Hologic (NASDAQ:HOLX) Announces Earnings Results

Hologic (NASDAQ:HOLX) posted its quarterly earnings data on Thursday. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05), FiscalAI reports. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion.

Hologic Trading Down 0.0%

Shares of Hologic stock traded down $0.03 on Friday, hitting $74.96. 173,594 shares of the company’s stock traded hands, compared to its average volume of 2,279,682. The company has a market capitalization of $16.73 billion, a price-to-earnings ratio of 30.22, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69. The company has a fifty day moving average of $74.88 and a two-hundred day moving average of $70.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. Hologic has a one year low of $51.90 and a one year high of $75.36.

Institutional Trading of Hologic

Hedge funds have recently modified their holdings of the stock. MUFG Securities EMEA plc bought a new stake in shares of Hologic during the second quarter valued at approximately $43,000. PenderFund Capital Management Ltd. bought a new stake in Hologic during the 3rd quarter valued at $47,000. EverSource Wealth Advisors LLC raised its holdings in Hologic by 88.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,536 shares of the medical equipment provider’s stock worth $100,000 after buying an additional 721 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of Hologic by 8.9% in the third quarter. Parallel Advisors LLC now owns 2,950 shares of the medical equipment provider’s stock valued at $199,000 after buying an additional 242 shares in the last quarter. Finally, Prelude Capital Management LLC acquired a new position in shares of Hologic during the third quarter valued at about $210,000. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on HOLX. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Wednesday. Morgan Stanley boosted their price target on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hologic has an average rating of “Hold” and a consensus target price of $79.31.

Key Headlines Impacting Hologic

Here are the key news stories impacting Hologic this week:

• Positive Sentiment: GYN Surgical outperformance provides a growth offset and a potential bright spot for future margins and revenue mix improvement. HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
• Neutral Sentiment: Company filed an earnings press release with full quarter detail — useful for parsing segment trends, cash flow and any updated guidance. Hologic Announces Financial Results for First Quarter of Fiscal 2026
• Neutral Sentiment: Analyst commentary and outlook pieces are assessing whether margin pressure is transitory (product mix, cost timing) or signals longer-term headwinds. Monitor upcoming conference call comments and any guidance changes. Examining the Future: Hologic’s Earnings Outlook
• Negative Sentiment: Reported EPS and revenue misses vs. Street estimates, which often pressures near-term stock performance and analyst revisions. Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates
• Negative Sentiment: Gross margin fell ~150 basis points and Diagnostics weakness was called out as the primary drag — a signal investors will watch for either stabilization or deeper pressure in upcoming quarters. HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
• Negative Sentiment: Market reaction: shares edged lower after the print as traders weigh near-term earnings risk and potential analyst downgrades. Hologic misses Q1 earnings and revenue estimates, shares edge lower

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.